← Back to Search

Proton Beam Therapy

Proton Therapy for Chordoma and Chondrosarcoma

N/A
Waitlist Available
Research Sponsored by Abramson Cancer Center at Penn Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age ≥ 18 years
Histologically confirmed diagnosis of chordoma or chondrosarcoma
Must not have
Tumors arising outside of the CNS
Histologies excluded: melanoma, other soft tissue or bony sarcomas, giant cell tumor aneurismal bone cyst, or metastatic lesions from other histologies
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 90 days
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether proton therapy is a safe and effective treatment for chordomas and chondrosarcomas.

Who is the study for?
This trial is for adults (18+) with confirmed chordoma or chondrosarcoma in the skull and spine, without metastatic disease. Participants must be fairly active (ECOG ≤2), have good bone marrow function, and not be pregnant. They can't join if they've had other cancers in the last two years or are on another treatment study.
What is being tested?
The study tests proton therapy's feasibility and immediate side effects for treating chordomas and chondrosarcomas, as well as its effectiveness and long-term side effects over time.
What are the potential side effects?
While specific side effects aren't listed here, proton therapy may include skin reactions at the treatment site, fatigue, headaches, hair loss near treated areas, nausea or hearing changes depending on tumor location.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
My diagnosis is either chordoma or chondrosarcoma.
Select...
I can take care of myself and perform daily activities.
Select...
My scans show no signs of cancer spread.
Select...
My blood tests show enough white cells and platelets.
Select...
My cancer originates in my skull or spine.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My cancer did not start in my brain or spinal cord.
Select...
My cancer is not melanoma, sarcoma, giant cell tumor, or aneurismal bone cyst.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~90 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 90 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Acute Toxicity
Chondrosarcoma
Secondary study objectives
Late toxicity

Side effects data

From 2022 Phase 1 & 2 trial • 40 Patients • NCT01839838
61%
Skin hyperpigmentation
29%
Localized edema
29%
Telangiectasia
11%
Superficial soft tissue fibrosis
7%
Pruritus
7%
Erythema
7%
Dermatitis radiation
7%
Fatigue
7%
Fibrosis of breast
7%
Dry skin
4%
Respiratory failure
4%
Enterocolitis infectious
4%
Generalized muscle weakness
4%
Intracranial hemorrhage
4%
Non-cardiac chest pain
4%
Reproductive system and breast disorders - Other, specify
4%
Sepsis
4%
Small intestine ulcer
4%
Breast pain
4%
Breast pigment change
4%
Chest pain
4%
Syncope
4%
Breast edema
4%
burning sensation of skin
4%
Breast tenderness
4%
Skin hypopigmentation
4%
Fracture
100%
80%
60%
40%
20%
0%
Study treatment Arm
APBI With Protons Phase 2
APBI With Protons Phase 1

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Proton groupExperimental Treatment1 Intervention
Proton radiation total dose 72.00 to 79.2 Gy(RBE) in 40-44 fractions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Proton Therapy
2013
Completed Phase 2
~320

Find a Location

Who is running the clinical trial?

Abramson Cancer Center at Penn MedicineLead Sponsor
413 Previous Clinical Trials
164,581 Total Patients Enrolled
Abramson Cancer Center of the University of PennsylvaniaLead Sponsor
359 Previous Clinical Trials
108,454 Total Patients Enrolled

Media Library

Proton Therapy (Proton Beam Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT01449149 — N/A
Chondrosarcoma Research Study Groups: Proton group
Chondrosarcoma Clinical Trial 2023: Proton Therapy Highlights & Side Effects. Trial Name: NCT01449149 — N/A
Proton Therapy (Proton Beam Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01449149 — N/A
~6 spots leftby Dec 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top